{
  "success": true,
  "pagesUsed": [
    0,
    1,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    20,
    21,
    22,
    23,
    24,
    26,
    27,
    28,
    29,
    30,
    31,
    32,
    34,
    35,
    36,
    37,
    38,
    39,
    40,
    41,
    42,
    43,
    45,
    46,
    47,
    48,
    49
  ],
  "modelUsed": "gemini-3-flash-preview",
  "interventions": {
    "studyInterventions": [
      {
        "id": "int_1",
        "name": "Upadacitinib",
        "type": {
          "id": "96c99527-ed26-40bc-b535-aee0a6783020",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "role": {
          "id": "d76ca47e-31a9-4122-99be-93155c6ed247",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Selective JAK1 inhibitor for the treatment of moderately to severely active rheumatoid arthritis.",
        "productIds": [
          "prod_1"
        ],
        "administrationIds": [
          "admin_1"
        ]
      },
      {
        "id": "int_2",
        "name": "Methotrexate (MTX)",
        "type": {
          "id": "b306bcf9-8821-474f-ba36-9c4787a06637",
          "code": "C54129",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Comparator",
          "instanceType": "Code"
        },
        "role": {
          "id": "35a26997-80e7-442e-8316-a3e4b70821cd",
          "code": "C54129",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Comparator",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Active comparator for Period 1; background therapy or discontinued in Period 2.",
        "productIds": [
          "prod_2"
        ],
        "administrationIds": [
          "admin_2"
        ]
      },
      {
        "id": "int_3",
        "name": "Placebo for Upadacitinib",
        "type": {
          "id": "624b4bd0-5448-456a-9546-0d8d5077f07d",
          "code": "C41132",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Placebo",
          "instanceType": "Code"
        },
        "role": {
          "id": "68f71aea-e8c8-4646-b276-4ed78837c5a7",
          "code": "C41132",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Placebo",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Matching placebo tablet for upadacitinib to maintain blinding.",
        "administrationIds": [
          "admin_3"
        ]
      },
      {
        "id": "int_4",
        "name": "Placebo for MTX",
        "type": {
          "id": "15f517c3-5c17-4371-83f5-7315c4451f74",
          "code": "C41132",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Placebo",
          "instanceType": "Code"
        },
        "role": {
          "id": "40382b3d-f1dc-436b-80ec-2105c0cae08e",
          "code": "C41132",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Placebo",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Matching placebo capsules for methotrexate to maintain blinding.",
        "administrationIds": [
          "admin_4"
        ]
      },
      {
        "id": "int_5",
        "name": "Folic acid",
        "type": {
          "id": "1451f5c1-038a-4c54-8c7a-955218f8cd6b",
          "code": "C54127",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Background Therapy",
          "instanceType": "Code"
        },
        "role": {
          "id": "06be7df5-e15b-4287-aa07-a27a6f2ac64f",
          "code": "C54127",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Background Therapy",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Required dietary supplement for subjects taking MTX."
      },
      {
        "id": "int_6",
        "name": "Corticosteroids",
        "type": {
          "id": "6a314f70-01da-4dfc-9183-2fafeac52efb",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "a78d0d90-5e0c-46a8-8c34-a215283d8f09",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Oral corticosteroids (≤ 10 mg/day prednisone equivalent) permitted if stable; rescue use allowed after Week 26."
      },
      {
        "id": "int_7",
        "name": "NSAIDs",
        "type": {
          "id": "8fbd21f0-4b78-4b4a-b9cc-e995b18ad866",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "f67a8d66-9ade-437c-8bab-55ef4ccab8ce",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Permitted if dose is stable for at least 1 week prior to first dose."
      },
      {
        "id": "int_8",
        "name": "Acetaminophen",
        "type": {
          "id": "6072020d-2fb1-40bf-94f0-2d9c9258e702",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "4ea09f9a-f032-42ce-a434-93b24e6fb6f9",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Permitted for pain management."
      },
      {
        "id": "int_9",
        "name": "csDMARDs",
        "type": {
          "id": "9ffae038-bb37-45cf-a90e-ac122f3e4b57",
          "code": "C54125",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Rescue Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "3419c2e7-acf1-424d-8825-76aa0dad7dad",
          "code": "C54125",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Rescue Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Initiation or adjustment allowed starting at Week 26 for subjects not achieving LDA."
      },
      {
        "id": "int_10",
        "name": "Strong CYP3A inhibitors/inducers",
        "type": {
          "id": "10ce11d5-d972-482d-aef5-069b63aef66d",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "697690c4-89ba-48e0-9516-f1dab871cfda",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Prohibited from Screening through the end of the study."
      },
      {
        "id": "int_11",
        "name": "High-potency opiates",
        "type": {
          "id": "fea0402a-ad67-40e0-bc1c-a6ed819891d5",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "9f2457ce-9c92-45a5-9c69-a96f18c12207",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Prohibited during the study; must be washed out 1 week prior to first dose."
      }
    ],
    "administrableProducts": [
      {
        "id": "prod_1",
        "name": "Upadacitinib tablet",
        "administrableDoseForm": {
          "id": "7de281f1-8942-4f88-ae7f-b57759ba7bc5",
          "code": "C42998",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Tablet",
          "standardCode": {
            "id": "ac0aed5f-329f-4b8d-9adb-a97020aa332d",
            "code": "C42998",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Tablet",
            "instanceType": "Code"
          },
          "instanceType": "Code"
        },
        "productDesignation": {
          "id": "18e72b5a-70bd-466d-ad17-11668622e4b8",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "AdministrableProduct",
        "strength": "15 mg, 30 mg",
        "substanceIds": [
          "sub_1"
        ],
        "manufacturer": "AbbVie"
      },
      {
        "id": "prod_2",
        "name": "Methotrexate capsule",
        "administrableDoseForm": {
          "id": "c51a1d98-7e4a-43d9-a2d2-34e6fdb37674",
          "code": "C25158",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Capsule",
          "standardCode": {
            "id": "6fd8c014-1ff6-4305-be68-bbb92b4f7c54",
            "code": "C25158",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Capsule",
            "instanceType": "Code"
          },
          "instanceType": "Code"
        },
        "productDesignation": {
          "id": "77bf0dad-da9e-4d62-87dc-036d4409c3b1",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "AdministrableProduct",
        "strength": "7.5 mg, 10 mg, 15 mg, 17.5 mg, 20 mg, 22.5 mg, 25 mg",
        "substanceIds": [
          "sub_2"
        ],
        "manufacturer": "Not specified"
      }
    ],
    "administrations": [
      {
        "id": "admin_1",
        "name": "Upadacitinib 15 mg QD",
        "instanceType": "Administration",
        "dose": "15 mg",
        "doseFrequency": "once daily",
        "route": {
          "code": "Oral",
          "codeSystem": "USDM",
          "decode": "Oral"
        },
        "duration": "Up to 260 weeks"
      },
      {
        "id": "admin_2",
        "name": "Upadacitinib 30 mg QD",
        "instanceType": "Administration",
        "dose": "30 mg",
        "doseFrequency": "once daily",
        "route": {
          "code": "Oral",
          "codeSystem": "USDM",
          "decode": "Oral"
        },
        "duration": "Period 1 and Period 2 (until Amendment 5)"
      },
      {
        "id": "admin_3",
        "name": "Methotrexate weekly",
        "instanceType": "Administration",
        "dose": "7.5 mg to 25 mg",
        "doseFrequency": "once weekly",
        "route": {
          "code": "Oral",
          "codeSystem": "USDM",
          "decode": "Oral"
        },
        "duration": "14 weeks (Period 1)"
      },
      {
        "id": "admin_4",
        "name": "Upadacitinib 15 mg Open-Label",
        "instanceType": "Administration",
        "dose": "15 mg",
        "doseFrequency": "once daily",
        "route": {
          "code": "Oral",
          "codeSystem": "USDM",
          "decode": "Oral"
        },
        "duration": "Starting with Amendment 5 for all subjects"
      }
    ],
    "substances": [
      {
        "id": "sub_1",
        "name": "Upadacitinib",
        "instanceType": "Substance",
        "description": "Selective Janus kinase 1 (JAK1) inhibitor; substance code ABT-494."
      },
      {
        "id": "sub_2",
        "name": "Methotrexate",
        "instanceType": "Substance",
        "description": "Antifolate antineoplastic and antirheumatic drug."
      }
    ],
    "medicalDevices": [],
    "summary": {
      "interventionCount": 11,
      "productCount": 2,
      "deviceCount": 0
    }
  },
  "rawResponse": {
    "interventions": [
      {
        "name": "Upadacitinib",
        "role": "Investigational Product",
        "description": "Selective JAK1 inhibitor for the treatment of moderately to severely active rheumatoid arthritis."
      },
      {
        "name": "Methotrexate (MTX)",
        "role": "Comparator",
        "description": "Active comparator for Period 1; background therapy or discontinued in Period 2."
      },
      {
        "name": "Placebo for Upadacitinib",
        "role": "Placebo",
        "description": "Matching placebo tablet for upadacitinib to maintain blinding."
      },
      {
        "name": "Placebo for MTX",
        "role": "Placebo",
        "description": "Matching placebo capsules for methotrexate to maintain blinding."
      },
      {
        "name": "Folic acid",
        "role": "Background Therapy",
        "description": "Required dietary supplement for subjects taking MTX."
      },
      {
        "name": "Corticosteroids",
        "role": "Concomitant Medication",
        "description": "Oral corticosteroids (≤ 10 mg/day prednisone equivalent) permitted if stable; rescue use allowed after Week 26."
      },
      {
        "name": "NSAIDs",
        "role": "Concomitant Medication",
        "description": "Permitted if dose is stable for at least 1 week prior to first dose."
      },
      {
        "name": "Acetaminophen",
        "role": "Concomitant Medication",
        "description": "Permitted for pain management."
      },
      {
        "name": "csDMARDs",
        "role": "Rescue Medication",
        "description": "Initiation or adjustment allowed starting at Week 26 for subjects not achieving LDA."
      },
      {
        "name": "Strong CYP3A inhibitors/inducers",
        "role": "Concomitant Medication",
        "description": "Prohibited from Screening through the end of the study."
      },
      {
        "name": "High-potency opiates",
        "role": "Concomitant Medication",
        "description": "Prohibited during the study; must be washed out 1 week prior to first dose."
      }
    ],
    "products": [
      {
        "name": "Upadacitinib tablet",
        "doseForm": "Tablet",
        "strength": "15 mg, 30 mg",
        "manufacturer": "AbbVie"
      },
      {
        "name": "Methotrexate capsule",
        "doseForm": "Capsule",
        "strength": "7.5 mg, 10 mg, 15 mg, 17.5 mg, 20 mg, 22.5 mg, 25 mg",
        "manufacturer": "Not specified"
      }
    ],
    "substances": [
      {
        "name": "Upadacitinib",
        "description": "Selective Janus kinase 1 (JAK1) inhibitor; substance code ABT-494."
      },
      {
        "name": "Methotrexate",
        "description": "Antifolate antineoplastic and antirheumatic drug."
      }
    ],
    "administrations": [
      {
        "name": "Upadacitinib 15 mg QD",
        "dose": "15 mg",
        "frequency": "once daily",
        "route": "Oral",
        "duration": "Up to 260 weeks"
      },
      {
        "name": "Upadacitinib 30 mg QD",
        "dose": "30 mg",
        "frequency": "once daily",
        "route": "Oral",
        "duration": "Period 1 and Period 2 (until Amendment 5)"
      },
      {
        "name": "Methotrexate weekly",
        "dose": "7.5 mg to 25 mg",
        "frequency": "once weekly",
        "route": "Oral",
        "duration": "14 weeks (Period 1)"
      },
      {
        "name": "Upadacitinib 15 mg Open-Label",
        "dose": "15 mg",
        "frequency": "once daily",
        "route": "Oral",
        "duration": "Starting with Amendment 5 for all subjects"
      }
    ],
    "devices": []
  }
}